Back to discover

Protein / target

Alpha-ketoglutarate-dependent dioxygenase alkB homolog 3

Encoded byALKBH3Q96Q83Homo sapiensSwiss-Prot
Small-molecule tractable
Druggability
Structure with Ligand
1
Research papers

Protein at a glance

Biological role

Broad specificity oxidative DNA demethylase

Strongest disease association

Liver Diseases

Via encoding gene ALKBH3 · Genetic evidence · score 0.42

Research activity

Emerging research

1 papers · latest 2023

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Dioxygenase that mediates demethylation of DNA and RNA containing 1-methyladenosine (m1A).

View complete UniProt function annotation

Dioxygenase that mediates demethylation of DNA and RNA containing 1-methyladenosine (m1A) (PubMed:12486230, PubMed:12594517, PubMed:16174769, PubMed:26863196, PubMed:26863410). Repairs alkylated DNA containing 1-methyladenosine (m1A) and 3-methylcytosine (m3C) by oxidative demethylation (PubMed:12486230, PubMed:12594517, PubMed:16174769, PubMed:25944111). Has a strong preference for single-stranded DNA (PubMed:12486230, PubMed:12594517, PubMed:16174769, PubMed:20714506). Able to process alkylated m3C within double-stranded regions via its interaction with ASCC3, which promotes DNA unwinding to generate single-stranded substrate needed for ALKBH3 (PubMed:22055184). Can repair exocyclic 3,N4-ethenocytosine adducs in single-stranded DNA (PubMed:25797601). Also acts on RNA (PubMed:12594517, PubMed:16174769, PubMed:16858410, PubMed:26863196, PubMed:26863410). Demethylates N(1)-methyladenosine (m1A) RNA, an epigenetic internal modification of messenger RNAs (mRNAs) highly enriched within 5'-untranslated regions (UTRs) and in the vicinity of start codons (PubMed:26863196, PubMed:26863410). Requires molecular oxygen, alpha-ketoglutarate and iron (PubMed:16858410, PubMed:22055184)

Subcellular location

NucleusCytoplasm
Domains and Gene Ontology detail (12)

Domains & features

Fe2OG dioxygenase

Gene Ontology

  • Cmitochondrion
  • Cnucleoplasm
  • Fbroad specificity oxidative DNA demethylase activity
  • Fferrous iron binding
  • FL-ascorbic acid binding
  • FmRNA N1-methyladenosine dioxygenase activity
  • Foxidative RNA demethylase activity
  • Pcell population proliferation
  • PDNA alkylation repair
  • PDNA repair
  • Pnegative regulation of cytoplasmic translation

286 aa · 33 kDa · 2 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell proliferation & survivalGO
View supporting evidence

Cell proliferation & survival

  • ·cell population proliferation

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene ALKBH3

Gene-level evidence surfaced through the gene ALKBH3 that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Liver Diseases
0.42Limited support

Genetic evidence dominant · Open Targets 0.25

Metabolic Syndrome
0.29Limited support

Genetic evidence dominant · Open Targets 0.18

Hypertension
0.12Preliminary

Genetic evidence dominant · Open Targets 0.07

Carcinoma, Hepatocellular
0.10Preliminary

Literature evidence dominant · Open Targets 0.08 · no direct causal or clinical evidence

Neoplasms
0.10Preliminary

Literature evidence dominant · Open Targets 0.08 · no direct causal or clinical evidence

View evidence synthesis (5)
Liver DiseasesLimited support
0.42
agreement 0.300.54
Genetic100%

Open Targets aggregate 0.25 · 1 independent evidence family

Metabolic SyndromeLimited support
0.29
agreement 0.170.41
Genetic100%

Open Targets aggregate 0.18 · 1 independent evidence family

HypertensionPreliminary
0.12
agreement 0.000.24
Genetic100%

Open Targets aggregate 0.07 · 1 independent evidence family

Carcinoma, HepatocellularPreliminary
0.10
agreement 0.000.38
Literature100%

Open Targets aggregate 0.08 · 1 independent evidence family · no direct causal or clinical evidence

NeoplasmsPreliminary
0.10
agreement 0.000.38
Literature100%

Open Targets aggregate 0.08 · 1 independent evidence family · no direct causal or clinical evidence

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Liver Diseases0.25
Metabolic Syndrome0.18
Carcinoma, Hepatocellular0.08
Neoplasms0.08
Uveal Melanoma0.08
Hypertension0.07

Tractability

Small moleculesEmerging

Feasibility evidence (structure with ligand and high-quality ligand) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (uniprot ubiquitination and database ubiquitination) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (7)
SM · Structure with LigandSM · High-Quality LigandSM · Med-Quality PocketPR · UniProt UbiquitinationPR · Database UbiquitinationPR · Half-life DataPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Research activity

1 papers · to 2023

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Recent

Europe PMC papers linked directly to this protein.